Eli Lilly’s up-to-$2.3 billion acquisition of Ajax Therapeutics is facing its first major public test, and the initial clinical data show why the pharma giant made the bet. The Ajax acquisition was a ...

File photo first issued 06/11/25 by the Ministry of Defence of an AJAX Armoured Fighting Vehicle (AFV). MPs have questioned whether the Army's troubled £6.3 billion Ajax light tank will ever be fit ...

Add Yahoo as a preferred source to see more of our stories on Google. The Ajax was seen in its first public running display at Tankfest 2024 at The Tank Museum in Dorset, but problems quickly emerged ...

From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or ...

You’re invited to participate in a series of special events to honour veterans and celebrate local history in Ajax as the town commemorates a significant event. The Town of Ajax is hosting a series of ...

Trials of the British Army's Ajax armoured vehicle will be "proceeding cautiously" after they were halted last year, a defence minister has said. A decision was made to stop using the Ajax after ...

General Dynamics said the safety of soldiers 'is, and has always been, our highest priority'. Trials of the Army's troubled Ajax armoured vehicles will resume "cautiously", with the defence minister ...

LONDON, April 28 (Reuters) - Britain's defence readiness minister Luke Pollard said he had agreed to restart the army's acceptance of Ajax armoured vehicles from General Dynamics with ‌strict controls ...

Eli Lilly LLY-2.33%decrease; down pointing triangle continued its recent buying spree, agreeing to pay up to $2.3 billion for Ajax Therapeutics in a deal that bolsters the drugmaker’s blood-cancer ...

Eli Lilly said on Monday it would buy privately held cancer drug developer Ajax Therapeutics for up to $2.3 billion in cash, as the U.S. drugmaker looks to expand its oncology pipeline. Lilly has been ...

Eli Lilly’s run of near-weekly acquisitions still shows no sign of letting up, with the Big Pharma now buying Ajax Therapeutics for its clinical-stage myelofibrosis therapy. At the center of the deal ...

Total consideration reaches up to $2.3 billion via upfront payment plus milestones tied to predefined clinical and regulatory achievements, subject to customary conditions and Hart-Scott-Rodino ...